Interim Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Net income	$ 12,676	$ 18,724
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	7,380	6,962
Provision for doubtful accounts receivable	501	503
Equity in earnings of unconsolidated investments	(2,804)	(2,081)
Distributions from unconsolidated investments	16	823
Gains on sale of restricted marketable securities	(687)	(98)
Deferred income taxes	(605)	(165)
Stock-based compensation	543	984
Changes in operating assets and liabilities:
Restricted cash and cash equivalents	(2,836)	(5,584)
Accounts receivable	(3,037)	7,814
Income tax receivable	3,779
Inventories	481	154
Prepaid expenses and other assets	(1,724)	(1,719)
Trade accounts payable	384	152
Accrued payroll	(16,243)	(16,680)
Amounts due to third party payors	471	(746)
Other current liabilities and accrued risk reserves	2,370	(810)
Entrance fee deposits	(578)	(102)
Other noncurrent liabilities	(140)	35
Deferred income	3,088	3,228
Net cash provided by operating activities	3,035	11,394
Cash Flows From Investing Activities:
Additions to and acquisitions of property and equipment	(2,972)	(6,160)
Investments in notes receivable	(200)
Collections of notes receivable	370	352
Change in restricted cash and cash equivalents	237	(2,043)
Purchase of restricted marketable securities	(24,343)	(12,220)
Sale of restricted marketable securities	23,394	13,570
Net cash used in investing activities	(3,514)	(6,501)
Cash Flows From Financing Activities:
Tax benefit from stock-based compensation	3	305
Dividends paid to preferred stockholders	(2,168)	(2,168)
Dividends paid to common stockholders	(4,146)	(3,804)
Issuance of common shares	5,578	5,953
Change in deposits	(82)	(153)
Net cash (used in) provided by financing activities	(815)	133
Net (Decrease) Increase in Cash and Cash Equivalents	(1,294)	5,026
Cash and Cash Equivalents, Beginning of Period	61,008	28,478
Cash and Cash Equivalents, End of Period	$ 59,714	$ 33,504